Corrigendum.

Abstract

Immunity, Inflammation and DiseaseVolume 11, Issue 1 e774 CORRIGENDUMOpen Access Corrigendum This article corrects the following: Symptomatology, prognosis, and clinical findings of Monkeypox infected patients during COVID-19 era: A systematic-review Vikash Jaiswal, Priyanshu Nain, Dattatreya Mukherjee, Amey Joshi, Mittal Savaliya, Angela Ishak, Nitya Batra, Dipansha Maroo, Deepak Verma, Volume 10Issue 11Immunity, Inflammation and Disease First Published online: October 11, 2022 First published: 23 January 2023 https://doi.org/10.1002/iid3.774AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat In Jaiswaled et al.,1 authors' discovered that the percentage values were incorrectly calculated. The values have been corrected to update percentage values in different section of the paper. The authors apologize for this error. In Results the symptoms recorded read “The major symptoms were rash (100%), fever (96%), and other important symptoms were upper respiratory symptoms (97%), headache (95%), vomiting (95%), oral ulcers (96%), conjunctivitis (96%), and lymphadenopathy (85%).” They should have read: “The major symptoms were rash (100%), fever (99%), and other important symptoms were upper respiratory symptoms (55%), lymphadenopathy (85%), headache (78%), vomiting (25%), oral ulcers (56%), and conjunctivitis (21%).” In Paragraph 3.3 the reported symptoms read “The major and most significant symptoms were rash 1078/1078 (100%), fever 1037/1075 (96%). Other important symptoms were upper respiratory symptoms 1026/1060 (97%), headache 1015/1068 (95%), vomiting 1011/1059 (95%), oral ulcers 1018/1057 (96%), conjunctivitis 1017/1058 (96%), and lymphadenopathy 905/1070 (85%).” They should have read: “The major and most significant symptoms were rash 1078/1078 (100%), fever 1037/1047 (99%). Other important symptoms were upper respiratory symptoms 563/1027 (55%), headache 797/1021 (78%), vomiting 251/1012 (25%), oral ulcers 570/1018 (56%), conjunctivitis 211/1017 (21%), and lymphadenopathy 886/1047 (85%).” In Paragraph 4.3 the clinical features read “Overwhelmingly, the clinical features of monkeypox are like those of smallpox. More than 90% patients of monkeypox clinically present with a fever, rash, headache, and upper respiratory symptoms and more than 80% patients have lymphadenopathy, oral ulcers, conjunctivitis, vomiting, and diarrhea as noted by this review.” They should have read “Overwhelmingly, the clinical features of monkeypox are like those of smallpox. Patients with monkeypox clinically present with a fever, rash, headache, lymphadenopathy, and upper respiratory symptoms and other less common symptoms which include oral ulcers, conjunctivitis, vomiting, and diarrhea as noted by this review.” In Supporting Information: Table 1, affected values have been corrected and uploaded online. Table 2 has been updated with the recalculated percentage points, shown in red. Table 2. Summary table of all monkeypox cases highlighting demographic, symptoms, management, and outcomes. Variables n/N (%) N 1078 Age (mean, SD) 20.66 ± 16.45 years Male, n (%) 583 [54%] Female, n (%) 489 [46%] NR 6 Country UK 2/10 [20%] Nigeria 1/10 [10%] Sierra Leone 1/10 [10%] DR Congo 3/10 [30%] Singapore 1/10 [10%] USA 1/10 [10%] Australia 1/10 [10%] Monkeypox viral DNA test RT PCR: 1074/1075 [99.9%] Symptoms Fever 1037/1047 [99%] Headache 797/1021 [78%] Lymphadenopathy 886/1047 [85%] [cervical lymphadenopathy is most common] Upper respiratory symptoms 563/1027 [55%] Rash 1078/1078 [100%] Oral ulcers 570/1018 [56%] Vomiting 251/1012 [25%] Conjunctivitis 211/1017 [21%] Management Antivirals 7/11 [63%] Antibiotics 4/10[40%] Length of hospitalization (mean) 13.3 ± 6.37 days Duration of management (mean) 5 days Outcomes Recovery- 19/20 [95%] Death: 1/20 [5%] REFERENCE 1Jaiswal, V, Nain, P, Mukherjee, D, et al. Symptomatology, prognosis, and clinical findings of monkeypox infected patients during COVID-19 era: a systematic review. Immun Inflamm Dis. 2022; 10:e722. doi:10.1002/iid3.722 Volume11, Issue1January 2023e774 This article also appears in:Monkeypox Collection January 2023 ReferencesRelatedInformation